UK AI Security Tests Reveal Anthropic and OpenAI Agents Attempted Unauthorized Actions 
Jetstar to Charge for Overhead Cabin Bags From February 
Meta AI Model Exploits Security Flaw During Cybersecurity Test, Raising AI Safety Concerns 
Moderna Wins FDA Approval for mFLUSIVA mRNA Flu Vaccine for Adults 50+ 
Novo Nordisk Raises 2025 Outlook Despite Wegovy Pill Miss and CagriSema Setback 
SanDisk Q4 Earnings Beat Estimates as Q1 Revenue Outlook Meets Expectations 
Infineon Raises 2026 Revenue Outlook as AI Data Center Demand Fuels Record Quarterly Sales 
DHL Q2 Profit Jumps 24% as Express Business Drives Growth 
DBS Raises 2025 Outlook After Record Q2 Profit Driven by Wealth Management 
Airbnb Stock Jumps After Q2 Earnings Beat, Strong 2026 Outlook 
Western Digital Q4 Earnings Beat Estimates as FY2027 Outlook Tops Expectations 
Alphabet Stock Slides as Google AI Pioneer Jeff Dean Exits to Launch Discovery Loop 
UOB Q2 Net Profit Rises 10% as Wealth Management Growth Boosts Earnings 
Qantas Shares Climb as Long-Haul Pilot Deal Eases Strike Concerns 
Alibaba Plans Revenue-Sharing Model for Qwen3.8-Max AI Commercial Users 
Sinopec Boosts Russian ESPO Oil Purchases as Middle East Supply Tightens 
WESTLAKE VILLAGE, Calif., March 14, 2018 -- MannKind Corporation (NASDAQ:MNKD) focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension, announced today that its Chief Executive Officer, Michael Castagna, will present at the Oppenheimer 28th Annual Healthcare Conference on Tuesday, March 20, 2018 at 3:20 PM (Eastern Time) at the Westin New York Grand Central.
Interested parties can access a link to the live webcast of the presentations from the News & Events section of the Company's website at http://www.mannkindcorp.com.
ABOUT MANNKIND CORPORATION
MannKind Corporation (NASDAQ:MNKD) focuses on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. MannKind is currently commercializing Afrezza® (insulin human) inhalation powder, the Company's first FDA-approved product and the only inhaled rapid-acting mealtime insulin in the United States, where it is available by prescription from pharmacies nationwide. MannKind is headquartered in Westlake Village, California, and has a state-of-the art manufacturing facility in Danbury, Connecticut. The Company also employs field sales and medical representatives across the U.S. For further information, visit www.mannkindcorp.com.
Company Contact:
Rose Alinaya
SVP Investor Relations
818-661-5000
[email protected]
